Chanana, Vishal
Hackett, Margaret
Deveci, Nazli
Aycan, Nur
Ozaydin, Burak
Cagatay, Nur Sena
Hanalioglu, Damla
Kintner, Douglas B.
Corcoran, Karson
Yapici, Sefer
Camci, Furkan
Eickhoff, Jens
Frick, Karyn M.
Ferrazzano, Peter
Levine, Jon E.
Cengiz, Pelin http://orcid.org/0000-0002-5682-5664
Funding for this research was provided by:
NIH-NINDS (R01 NS111021, K08 NS088563, 1K08NS078113)
NIH (P50HD105353)
Article History
Received: 4 September 2023
Accepted: 7 December 2023
First Online: 4 January 2024
Declarations
:
: All procedures were carried out in adherence to the NIH Guide for the Care and Use of Laboratory Animals using protocols reviewed and approved by the Institutional Animal Care and Use Committee at the School of Medicine and Public Health of the University of Wisconsin-Madison, which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
: All authors give consent for publication.
: This work was supported by R01NS111021 to Pelin Cengiz. Jon E. Levine is supported by R01DK121559-01, R21HD102172-01, and U24MH123422-01. Karyn M. Frick is supported by R01MH107886, Alzheimer’s Association ABA-22-973796, and multiple grants from the UWM Research Foundation and UWM Graduate School. Dr. Frick is a co-founder and the Chief Scientific Officer of Estrigenix Therapeutics, Inc., a company which aims to improve women's health by developing safe, clinically proven treatments for the mental and physical effects of menopause. The rest of the authors do not have any conflicts of interests to declare.